Ramanuj DasGupta
Overview
Explore the profile of Ramanuj DasGupta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2726
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Narmada B, Khakpoor A, Shirgaonkar N, Narayanan S, Aw P, Singh M, et al.
J Hepatol
. 2024 Feb;
81(1):42-61.
PMID: 38423478
Background & Aims: Hepatitis B surface antigen (HBsAg) loss or functional cure (FC) is considered the optimal therapeutic outcome for patients with chronic hepatitis B (CHB). However, the immune-pathological biomarkers...
12.
Dehkordi S, Wong I, Ni J, Luebeck J, Zhu K, Prasad G, et al.
bioRxiv
. 2024 Jan;
PMID: 38168210
Oncogene amplification is a major driver of cancer pathogenesis. Breakage fusion bridge (BFB) cycles, like extrachromosomal DNA (ecDNA), can lead to high copy numbers of oncogenes, but their impact on...
13.
Tan D, Ng C, Muthiah M, Yong J, Chee D, Teng M, et al.
Metabolism
. 2023 Nov;
152:155744.
PMID: 38029839
Background: High body mass index (BMI) is a major risk factor for cancer development, but its impact on the global burden of cancer remains unclear. Methods: We estimated global and...
14.
Reolo M, Otsuka M, Seow J, Lee J, Lee Y, Nguyen P, et al.
Front Immunol
. 2023 Jun;
14:1182016.
PMID: 37377962
Introduction: Despite recent advances in immunotherapy for hepatocellular carcinoma (HCC), the overall modest response rate underscores the need for a better understanding of the tumor microenvironment (TME) of HCC. We...
15.
Cappellesso F, Orban M, Shirgaonkar N, Berardi E, Serneels J, Neveu M, et al.
Nat Cancer
. 2022 Dec;
3(12):1464-1483.
PMID: 36522548
Solid tumors are generally characterized by an acidic tumor microenvironment (TME) that favors cancer progression, therapy resistance and immune evasion. By single-cell RNA-sequencing analysis in individuals with pancreatic ductal adenocarcinoma...
16.
DasGupta R, Yap A, Yaqing E, Chia S
WIREs Mech Dis
. 2022 Sep;
15(1):e1585.
PMID: 36168283
Cancer treatment is gradually evolving from the classical use of nonspecific cytotoxic drugs targeting generic mechanisms of cell growth and proliferation. Instead, new "patient-specific treatment paradigms" that are based on...
17.
Ong L, Chia S, Wong S, Zhang X, Chua H, Loo J, et al.
Front Bioeng Biotechnol
. 2022 Sep;
10:952726.
PMID: 36147524
Inter-patient and intra-tumour heterogeneity (ITH) have prompted the need for a more personalised approach to cancer therapy. Although patient-derived xenograft (PDX) models can generate drug response specific to patients, they...
18.
Joanito I, Wirapati P, Zhao N, Nawaz Z, Yeo G, Lee F, et al.
Nat Genet
. 2022 Jun;
54(7):963-975.
PMID: 35773407
The consensus molecular subtype (CMS) classification of colorectal cancer is based on bulk transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed 373,058 single-cell transcriptomes from 63 patients, focusing...
19.
Akincilar S, Chua J, Ng Q, Chan C, Eslami-S Z, Chen K, et al.
Nucleic Acids Res
. 2022 Jun;
51(1):1-16.
PMID: 35697349
Transcriptional reactivation of hTERT is the limiting step in tumorigenesis. While mutations in hTERT promoter present in 19% of cancers are recognized as key drivers of hTERT reactivation, mechanisms by...
20.
Nguyen P, Wasser M, Tan C, Lim C, Lai H, Seow J, et al.
Nat Commun
. 2022 Mar;
13(1):1441.
PMID: 35301339
Immune evasion is key to cancer initiation and later at metastasis, but its dynamics at intermediate stages, where potential therapeutic interventions could be applied, is undefined. Here we show, using...